Can This Maverick Biotech Become the Frontrunner in the Fight Against Alzheimer's?
If you had invested $10,000 in shares of mid-cap biotech Cassava Sciences (NASDAQ: SAVA) at the beginning of the year, your position would have grown to a stunning $99,650 as of Feb. 3. With the stock achieving 10-bagger status in a little over a month, many investors wonder if the stock can still make them rich if they buy now.
Alzheimer's affects 5 million Americans, and no new therapies have been approved for decades. I believe that Cassava can change that. The company still only has a market cap of $2.66 billion after its recent run-up, despite having the potential blockbuster drug, simufilam, in its pipeline. Just what are the odds of its success?
Image source: Getty Images.
Source Fool.com
